Full Text View
Tabular View
No Study Results Posted
Related Studies
Umbilical Cord Blood Transplantation in Treating Patients With Severe Aplastic Anemia, Malignant Thymoma, or Myelodysplasia
This study is ongoing, but not recruiting participants.
First Received: November 1, 1999   Last Updated: February 6, 2009   History of Changes
Sponsors and Collaborators: Case Comprehensive Cancer Center
National Cancer Institute (NCI)
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00003336
  Purpose

RATIONALE: Umbilical cord blood transplantation may allow doctors to give higher doses of chemotherapy or radiation therapy and kill more cancer cells.

PURPOSE: This phase II trial is studying how well umbilical cord blood transplantation works in treating patients with severe aplastic anemia, malignant thymoma, or myelodysplasia.


Condition Intervention Phase
Leukemia
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases
Biological: anti-thymocyte globulin
Drug: busulfan
Drug: cyclophosphamide
Drug: melphalan
Drug: methylprednisolone
Procedure: bone marrow ablation with stem cell support
Procedure: umbilical cord blood transplantation
Radiation: radiation therapy
Phase II

Study Type: Interventional
Study Design: Treatment, Open Label
Official Title: A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Patients With Severe Aplastic Anemia, Inborn Errors in Metabolism, or Inherited Hematologic Stem Cell Disorders

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Event-free survival by disease assessment at 100 days and at 6, 9, 12, 18, and 24 months [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Umbilical cord blood donor engraftment by chimerism and complete blood count (CBC) at time of myeloid recovery, 100 days and at 6, 9, 12, 18, and 24 months [ Designated as safety issue: No ]

Estimated Enrollment: 90
Study Start Date: January 1998
Detailed Description:

OBJECTIVES:

  • Determine the rates of durable engraftment in patients with severe aplastic anemia, myelodysplastic syndrome, inborn errors of metabolism, or inherited hematopoietic disorders, refractory to medical management, who are undergoing high-dose chemoradiotherapy followed by unrelated cord blood (UCB) transplantation.
  • Evaluate the rate and quality of immunologic reconstitution in this patient population.

OUTLINE: Patients are stratified according to weight (under 45 kg vs over 45 kg).

Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT). The regimen varies according to the underlying cause of the anemia, but could include busulfan, cyclophosphamide or melphalan, anti-thymocyte globulin or methylprednisolone, and/or radiation therapy. One day after the conditioning regimen is completed, patients receive the UCBT.

Patients are followed weekly for 3 months, at 6 months, then every 6 months for 2.5 years, then annually thereafter.

PROJECTED ACCRUAL: A total of 4-90 patients will be accrued for this study within 5 years.

  Eligibility

Ages Eligible for Study:   up to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically confirmed diagnosis of severe aplastic anemia based on bone marrow cellularity of less than 20%
  • Must meet at least two of the following criteria:

    • Granulocyte count less than 500/mm^3
    • Platelet count less than 20,000/mm^3
    • Reticulocyte count less than 50,000/mm^3
  • Following etiologies eligible:

    • Fanconi's anemia
    • Hypoplastic leukemia
    • Monosomy 7
    • Drug exposure (chloramphenicol, NSAIDS)
    • Viral exposure (EBV, hepatitis, parvovirus, HIV)
    • Nutritional deficiencies
    • Thymoma
    • Paroxysmal nocturnal hemoglobinuria
    • Amegakaryocytic thrombocytopenia OR
  • Histologically confirmed myelodysplastic syndrome (MDS) that is refractory to medical management or with cytogenic abnormalities predictive of transformation into acute leukemia, including 5q-, 7q-, monosomy 7, or trisomy 8
  • The following etiologies only are eligible:

    • Refractory anemia
    • Refractory anemia with ringed sideroblasts
    • De novo primary MDS
    • Therapy-related secondary MDS OR
  • Confirmed diagnosis of inherited hematopoietic disorder that is refractory to medical management
  • Following etiologies eligible:

    • Severe combined immunodeficiency
    • Familial erythrophagocytic lymphohistiocytosis
    • Wiskott-Aldrich syndrome
    • Kostmann's syndrome (infantile histiocytosis)
    • Chronic granulomatous disease
    • Leukocytic adhesion deficiency
    • Chediak-Higashi syndrome
    • Paroxysmal nocturnal hemoglobinuria
    • Fanconi's anemia
    • Dyskeratosis congenita
    • Diamond-Blackfan anemia
    • Amegakaryocytic thrombocytopenia
    • Osteopetrosis
    • Gaucher's disease
    • Lesch-Nyhan syndrome
    • Mucopolysaccharidoses
    • Lipodoses
  • Autologous or haploidentical related peripheral blood stem cells available as backup
  • Serologically matched umbilical cord blood unit available in the New York Blood Center's Placental Blood Project, or other acceptable umbilical cord blood registry

PATIENT CHARACTERISTICS:

Age:

  • 55 and under

Performance status:

  • Zubrod 0-1
  • Karnofsky 80-100%

Life expectancy:

  • At least 3 months

Hematopoietic:

  • See Disease Characteristics

Hepatic:

  • ALT/AST no greater than 4 times normal
  • Bilirubin no greater than 2.0 mg/dL

Renal:

  • Creatinine no greater than 2.0 mg/dL
  • Creatinine clearance at least 50 mL/min

Cardiovascular:

  • Normal cardiac function by echocardiogram or radionuclide scan
  • Shortening fraction or ejection fraction at least 80% normal for age
  • Non-Fanconi patients with acquired or congenital cardiomyopathy may receive melphalan as a substitute for cyclophosphamide

Pulmonary:

  • FVC and FEV_1 at least 60% of predicted for age
  • DLCO at least 60% of predicted in adult patients

Other:

  • No active concurrent malignancy
  • No active infection
  • Not pregnant or nursing
  • HIV negative
  • Must have an available serologic matched Umbilical Cord Blood Unit (UCBU) in the New York Blood Center's Placental Blood Project, or other acceptable Umbilical Cord Blood (UCB) registry

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • Not specified

Chemotherapy:

  • No concurrent cytotoxic chemotherapy

Endocrine therapy:

  • No concurrent immunosuppressive medications

Radiotherapy:

  • No concurrent radiotherapy

Surgery:

  • Not specified
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00003336

Locations
United States, Ohio
Case Comprehensive Cancer Center
Cleveland, Ohio, United States, 44106-7284
Sponsors and Collaborators
Case Comprehensive Cancer Center
Investigators
Study Chair: Mary J. Laughlin, MD Case Comprehensive Cancer Center
  More Information

Additional Information:
Publications:
Study ID Numbers: CDR0000066307, CASE-CWRU-5Y97, NCI-G98-1431, CASE-5Y97
Study First Received: November 1, 1999
Last Updated: February 6, 2009
ClinicalTrials.gov Identifier: NCT00003336     History of Changes
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
refractory anemia
refractory anemia with ringed sideroblasts
de novo myelodysplastic syndromes
previously treated myelodysplastic syndromes
secondary myelodysplastic syndromes
atypical chronic myeloid leukemia
myelodysplastic/myeloproliferative disease, unclassifiable
childhood myelodysplastic syndromes

Study placed in the following topic categories:
Anti-Inflammatory Agents
Melphalan
Immunologic Factors
Precancerous Conditions
Aplastic Anemia
Methylprednisolone
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Antiemetics
Prednisolone acetate
Cyclophosphamide
Hormones
Neuroprotective Agents
Refractory Anemia
Leukemia
Preleukemia
Anemia, Refractory
Anemia, Aplastic
Neoplasm Metastasis
Alkylating Agents
Myelodysplastic Myeloproliferative Disease
Methylprednisolone Hemisuccinate
Antineoplastic Agents, Hormonal
Hematologic Diseases
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
Myelodysplastic Syndromes
Myeloproliferative Disorders
Anemia
Methylprednisolone acetate
Leukemia, Myeloid

Additional relevant MeSH terms:
Anti-Inflammatory Agents
Molecular Mechanisms of Pharmacological Action
Precancerous Conditions
Immunologic Factors
Antineoplastic Agents
Methylprednisolone
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Antiemetics
Prednisolone acetate
Cyclophosphamide
Hormones
Neuroprotective Agents
Leukemia
Preleukemia
Pathologic Processes
Therapeutic Uses
Syndrome
Anemia, Aplastic
Alkylating Agents
Methylprednisolone Hemisuccinate
Neoplasms by Histologic Type
Disease
Antineoplastic Agents, Hormonal
Hematologic Diseases
Myelodysplastic Syndromes
Gastrointestinal Agents
Anemia
Myeloproliferative Disorders
Methylprednisolone acetate

ClinicalTrials.gov processed this record on September 01, 2009